NYSE:AORTMedical Equipment
Artivion (AORT) Is Down 7.6% After Revenue Miss But Strong 2026 Guidance And Trial Data
In the past week, Artivion reported fourth-quarter 2025 results showing revenue of US$115.99 million and net income of US$2.43 million, marking a move from a loss a year earlier and contributing to full-year revenue of US$441.33 million and net income of US$9.77 million.
At the same time, new clinical data from the NEXUS TRIOMPHE and AMDS PERSEVERE trials reinforced the performance of Artivion’s aortic arch therapies, which management now cites as central to its 2026 revenue guidance of...